Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial

Bone Marrow Transplantation 2026 Open access

Read full text
Authors: Ruben Van Dijck, Bronno van der Holt, A. E. C. Broers, M. D. Hazenberg, T. Devos, M. W. M. van der Poel, Dimitri Breems, Lien Deleu, B. Schuthof, C. M. C. van Hooije, J. J. Cornelissen, N. P. M. Schaap
+1 more P. A. W. te Boekhorst
DOI: 10.1038/s41409-026-02841-0
Cited by: 2
References: 8

Abstract

For eligible myelofibrosis (MF) patients, allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment. Based on possible better transplant outcomes in responding patients [ 1 ], current EBMT/ELN-guidelines recommend pre-transplant spleen-directed therapy with JAK-inhibitors, but also emphasize the unmet need of data on the use of newer generation JAK-inhibitors in this setting [ 2 , 3 ]. Transplant-eligible MF patients were excluded from all landmark JAK-inhibitor trials. The single-arm, non-randomized HOVON-134 trial specifically aimed to answer this question: Is the use of the JAK1-sparing JAK2/IRAK1/ACVR1-inhibitor pacritinib (PAC) feasible in transplant-eligible MF patients, particularly with regards to spleen and symptom responses, safety and patients’ ability to proceed towards intended alloHSCT.

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Multiple Myeloma Research and Treatments Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Bone Marrow Transplantation
Publisher
Springer Science and Business Media LLC
Volume
61
Issue
6
Pages
747–749
Publication date
18 March 2026
Language
EN